ContraFect Corp (NASDAQ:CFRX) saw a significant growth in short interest in July. As of July 31st, there was short interest totalling 392,500 shares, a growth of 16.5% from the June 30th total of 337,000 shares. Currently, 0.7% of the company’s stock are sold short. Based on an average daily volume of 514,900 shares, the days-to-cover ratio is currently 0.8 days.

ContraFect stock traded down $0.01 during mid-day trading on Thursday, hitting $0.39. The company had a trading volume of 161,117 shares, compared to its average volume of 922,073. The company has a quick ratio of 4.23, a current ratio of 4.23 and a debt-to-equity ratio of 0.20. The business has a 50 day simple moving average of $0.47. ContraFect has a 12 month low of $0.35 and a 12 month high of $2.63. The company has a market capitalization of $32.31 million, a P/E ratio of -1.05 and a beta of 0.07.

Institutional investors have recently added to or reduced their stakes in the business. Oracle Investment Management Inc. increased its position in shares of ContraFect by 13.1% in the 2nd quarter. Oracle Investment Management Inc. now owns 6,356,649 shares of the biotechnology company’s stock worth $3,242,000 after purchasing an additional 735,450 shares during the last quarter. Hartwell J M Limited Partnership boosted its stake in ContraFect by 40.0% during the 2nd quarter. Hartwell J M Limited Partnership now owns 140,000 shares of the biotechnology company’s stock valued at $71,000 after purchasing an additional 40,000 shares during the period. Trellus Management Company LLC acquired a new position in ContraFect during the 2nd quarter valued at about $295,000. SG Americas Securities LLC acquired a new position in ContraFect during the 2nd quarter valued at about $343,000. Finally, White Pine Capital LLC boosted its stake in ContraFect by 207.9% during the 1st quarter. White Pine Capital LLC now owns 907,430 shares of the biotechnology company’s stock valued at $361,000 after purchasing an additional 612,700 shares during the period. 39.19% of the stock is currently owned by institutional investors and hedge funds.

CFRX has been the topic of several research reports. ValuEngine upgraded ContraFect from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Chardan Capital reissued a “buy” rating and issued a $1.50 target price on shares of ContraFect in a report on Wednesday, May 15th. Finally, Maxim Group initiated coverage on ContraFect in a report on Tuesday, June 11th. They issued a “buy” rating on the stock.

ContraFect Company Profile

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.

Read More: Trading on Margin

Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.